Slides
Page 1
angiodynamics Canaccord Genuity 46th Annual Growth Conference August 11 , 2026 Jim Clemmer , President & CEO Stephen Trowbridge , Executive Vice President & CFO
Page 2
Forward looking statements 2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “projects,” “believes,” “seeks,” “estimates,” “optimistic,” or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics’ expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics’ technology or assertions that AngioDynamics’ technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, tariffs, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of salesefforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2026. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason. Notice Regarding Non-GAAP Financial Measures Management uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics’ business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to,financial reporting measures prepared in accordance with GAAP. In this presentation, AngioDynamics has reported pro forma results, adjusted EBITDA (income before interest, taxes, depreciation and amortization and stock-based compensation); adjusted net income and adjusted earnings per share. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics’ performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics’ underlying business. Management encourages investors to review AngioDynamics’ financial results prepared in accordance with GAAP to understand AngioDynamics’ performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics’ financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.
Page 3
AngioDynamics Our proven success positions us for sustained growth and profitability in key markets. 2020 - Today Today & Beyond Drove Performance and Built a More Dynamic Growth Focused Company Med Tech Growth & Sales Mix (%) 16% 47% FY20 FY26 Positioned for Sustained Profitable Growth Strengthened Financial Position • Delivered accelerated growth, streamlined operations, and improved margin performance Sharpened Portfolio Focus • Active portfolio management to scale high -growth MedTech opportunities Accelerated Innovation • Expanded MedTech leadership through innovation, strategic M&A, clinical investment, and meaningful physician engagement Expanding Market Potential • Growing TAM as clinical data unlocks new indications across MedTech franchises Fueling Innovation • Increasing R&D investment to deliver breakthrough technologies and long - term value Accelerating Commercial Investment • Building a stronger go -to-market engine in Cardiovascular and Prostate to capture growth opportunities $41M $150M +24% CAGR Robust Product Pipeline • Leveraging leading platforms to accelerate innovation and support sustained expansion in attractive, high -growth markets 3
Page 4
4 Unrivaled Innovation Our synergistic portfolio is focused on providing comprehensive solutions to help treat patients within two of the largest global healthcare markets MINI STICK MAX Prostate Care $930M U.S. TAM Med Tech Med Device Peripheral Artery Disease (PAD) $800M U.S. TAM Venous Thromboembolism (VTE) $5.5B U.S. TAM Cardiovascular Disease Cancer A R T E R I A L V E N O U S
Page 5
$145 $151 $157 $161 $165 $166 $170 $41 $56 $79 $96 $106 $127 $150 $186 $206 $235 $257 $271 $293 $320 FY20 A FY21 A FY22 A FY23 A FY24 A FY25 A FY26 A Pro Forma Fiscal Year Net Sales ($M) Med Device Med Tech 5 Demonstrated Med Tech Growth Execution 5 Med Tech ~22% of Total Med Tech ~47% of Total +18.4%
Page 6
6 Cardiovascular Arterial Since its launch in September 2020, Auryon has been used in nearly 180,000 procedures and surpassed $255M in cumulative sales Peripheral Artery Disease (PAD) • Hospital market growth fuels ASP stability • New and expanded reimbursement coverage solidifies atherectomy’s place in treatment algorithms • AMBITION BTK further positions us for market expansion Addressable Procedures M A R K E T D Y N A M I C S TAM $800M Served Market Auryon is versatile and effective at treating all types of lesions both through the femoral and radial approaches Comprehensive Treatment Capability • Effectively addresses all lesion types, including severe calcification and in -stent restenosis Precision and Safety • Optimized technology delivers energy without thermal damage, with built -in aspiration to minimize embolization risk Efficiency and Proven Outcomes • Portable, easy-to-use system with clinically validated performance and high patency rates
Page 7
7 Cardiovascular Venous Venous Thromboembolism (VTE) represents an attractive, high growth, underpenetrated market opportunity TAM $5.5B PE $2.4B DVT $2.8B Right Heart $280M M A R K E T D Y N A M I C S PE + DVT = Venous Thromboembolism (VTE) • Mechanical Thrombectomy for PE is estimated to have penetrated ~20% of the TAM • Mechanical Thrombectomy for DVT is estimated to have penetrated ~15% of the TAM Right Heart Cardiac Thrombus & Emboli • Growth is driven by rising increase in endocarditis and an aging population • More interventionalists embrace percutaneous techniques and the structural heart market is expanding
Page 8
8 Mechanical Thrombectomy Proprietary funnel cannula technology with the ability to have aspiration and simultaneous reinfusion with AngioVac or off-circuit manual aspiration control with AlphaVac Aspiration & Simultaneous ReinfusionAlphaVac Indicated for Treatment of Pulmonary Embolism • Minimally invasive treatment used to remove large blood clots, or thrombi, and other material from the venous system (veins) • On-circuit aspiration provides surgical results via percutaneous access by simultaneously reinfusing blood back in the patient’s body, minimizing blood loss Proprietary FUNNEL Manual Aspiration HANDLE Large Bore Aspiration CANNULA Complete system significantly improving reduction in clot burden vs. competitive technologies *Actual case result • Minimally invasive treatment used to treat PE and remove large blood clots, or thrombi, and other material from the venous system (veins), including the pulmonary arteries • Manual aspiration control enables precise suction, enhanced physician control, and improved maneuverability for wireless navigation between the PA's
Page 9
9 APEX – AV Pivotal Study AlphaVac received FDA clearance for PE following APEX-AV study demonstrating efficacy and significantly improved reduction in clot burden vs. competitive technologies Number of Sites 25 US Sites Number of Patients 122 Timeline Oct. 2022 – Dec 2023 Significant reduction in the RV/LV ratio • Significant improvement in the RV function Significant reduction in clot burden • Large funnel size (33 Fr) may aid in reducing the clot burden Procedure efficiency • Atraumatic tip provides easy and efficient navigation in the PAs • Ability to minimize blood loss • Short procedure time APEX (AngioDynamics) FLARE (Inari/Stryker) EXTRACT-PE (Penumbra) Reduction in Clot Burden 35.1% 9.3% 11.3%
Page 10
10 Prostate Cancer Backed by real world evidence and compelling clinical data, NanoKnife is a one-of-a-kind technology poised to change the standard of care of men with prostate cancer Intermediate Risk M A R K E T D Y N A M I C S Prostate Cancer is Prevalent, On the Rise & Debilitating • The most diagnosed male cancer in 112 countries, including the U.S. • Incidence projected to double by 2040 • Focal therapy is less than 7% penetrated into the Intermediate Risk addressable market Only Function-preserving Therapy that Uses Electricity to Destroy Prostate Tumors • Destroys targeted tissue with precise margins, preserving vital structures and tissue integrity • Backed by real world evidence and compelling clinical data, NanoKnife is a one -of-a-kind technology poised to change the standard of care of men with prostate cancer • NanoKnife safely & effectively treats prostate tumors while avoiding the high incidence of erectile dysfunction and incontinence associated with radical surgery and radiation Focal Therapy $60M TAM $930M
Page 11
11 Irreversible Electroporation (IRE) Preserves the underlying structure of tissue giving physicians a more precise tool PROBE PLACEMENT NanoKnife can be confidently used in all segments of an organ. DECELLULARIZATION Destroys targeted tissue with precise treatment margins. NON-THERMAL Spares vital structures by retaining the structural integrity of tissue.3 REVASCULARIZATION Facilitates functional tissue regeneration post-ablation. Only IRE device FDA cleared for prostate tissue Efficiently treats all segments of the prostate Easy clinical integration Significantly reduces quality of life side -effects caused by other therapeutic options
Page 12
12 PRESERVE Pivotal Study NanoKnife safely & effectively treats prostate tumors while avoiding the high incidence of erectile dysfunction and incontinence associated with radical surgery and radiation IRE Radical Surgery Radiation Therapy Erectile Function (9%) (51%) (30%) Urinary Continence (1.2%) (41%) (8%) Change from baseline at 1 year Number of Sites 17 US Sites Number of Patients 121 Primary Endpoint Follow Up 12 Months Efficacy 84% of patients were free from clinically significant in- field disease Safety 3.3% of patients had a device related SAE, all of which resolved 24-month Data: No New Treatment Failures; 97% with PSA Below Baseline
Page 13
13 FY 2026 Key Takeaways Continued commercial and operational execution drives AngioDynamics’ accelerated and profitable growth. Total +9.4% YoY Revenue Growth* Med Tech +18.4% Med Device +2.5% Auryon +17.7% Med Tech YoY Revenue Growth* Mech Thrombectomy 13.4% NanoKnife Probes +28.7% Focus on Profitability Balance Sheet Strength • Ended fiscal year with $53.9M in Cash • Zero debt with flexibility of revolving line of credit • Generated ~$3.1M of cash from operations in the year • Will generate positive cash flow from operations in FY27 • Pro forma Adjusted EBITDA** of $13.2M Continued Execution • Net sales of $320.2M, +9.4% YoY growth • Med Tech segment sales of $150.0M, +18.4% YoY growth • Med Device segment sales of $170.2M, +2.5% YoY growth *All growth rates are pro forma ** Pro forma Adjusted EBITDA excludes the $5.0 million milestone payment received from Spectrum Vascular in Q3 of FY 2026
Page 14
14 Fiscal Year 2027 Guidance supported by balance sheet strength $320 $336 - $341 FY 2026 A FY 2027 G FY 2026 Net Sales ($M) Med Device Med Tech *Guidance was issued in conjunction with fiscal Q4 FY 2026 earnings call on July 14, 2026 +12 - 15% Med Tech Metric Current Guidance Net Sales $336.0M - $341.0M Med Tech Net Sales Growth +12% - 15% Med Device Net Sales Growth Flat Gross Margin 54% – 55% Adjusted EBITDA +$13.0M - $16.0M Adjusted EPS ($0.29) – ($0.24) Flat Med Device FY 2027 Financial Guidance*
Page 15
Strong Product & Clinical Pipeline Leveraging our leading platforms to fuel innovation, market expansion, and long-term shareholder value in key growth markets Platform FY26 & Earlier $7.2B US TAM FY27 – FY31 $10.9B US TAM Peripheral Artery Disease: $800M US TAM IVL Indication DVT: $2.8B US TAM Coronary: $900M US TAM Pulmonary Embolism: $2.4B US TAM Right Heart: $280M US TAM Infective Endocarditis Indication DVT: $2.8B US TAM Left Heart: $760M US TAM Prostate Cancer: $930M US TAM BPH: $1.9B US TAM 15
Page 16
16 Ongoing Clinical Initiatives to Support Growth Initiative Purpose Overview AMBITION BTK Increased utilization within the below the knee critical limb ischemia (CLI) disease state A randomized controlled trial of the Auryon Atherectomy System + balloon angioplasty vs. standard angioplasty alone for below-the-knee lesions with critical limb ischemia (up to 224 patients / 30 sites + 1,500- patient registry). RECOVER-AV Increased European adoption A multi-center, multi-national, single-arm study of the AlphaVac F1885 System for mechanical thrombectomy in the treatment of acute, intermediate-risk pulmonary embolism (PE). APEX-Return Enables collection, filtration, and reinfusion of aspirated blood during thrombectomy; addresses market feedback on blood loss An IDE-approved study of the AlphaReturn blood management system, evaluating key safety and effectiveness endpoints, including device- related adverse events and procedural outcomes. PAVE Indication expansion into right- sided infective endocarditis (RSIE) A prospective, single-arm, multicenter feasibility trial that will enroll up to 30 patients with RSIE at up to six U.S. centers. In August 2023, the AngioVac System received an FDA Breakthrough Device designation for the removal of right heart vegetation. RELIEF Indication expansion into benign prostatic hyperplasia (BPH) A feasibility study evaluating irreversible electroporation (IRE), for the treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). IRRADIANT Expanded utilization in prostate cancer treatment continuum A randomized controlled trial evaluating a boost using IRE technology to a standard radiation therapy boost, both paired with a reduced course of whole gland radiation therapy, across 224 patients at Memorial Sloan Kettering (MSK).
Page 17
17 AngioDynamics Investment Summary Our MedTech segment operates in large, growing clinical markets, supported by differentiated technologies and proven clinical outcomes. Attractive MedTech Platforms in High -Value Markets We have a strong track record of active portfolio management, disciplined R&D investment, successful clinical and regulatory expansion, and customer-centric sales and marketing execution. Demonstrated Execution and Portfolio Discipline Our Med Device segment generates cash flow that funds targeted investments to accelerate MedTech innovation and growth. Self-Funded Growth Model We maintain a solid financial foundation with no debt, providing flexibility to invest, scale, and pursue strategic opportuni ties. Strong, Debt-Free Balance Sheet We achieved adjusted EBITDA positivity in FY2025, built on that progress in FY2026, and are now advancing toward free cash flow positivity in FY2027, reflecting improving operating leverage and margin expansion. Clear Path to Profitability and Cash Generation With focused strategy, financial strength, and innovation-driven growth, AngioDynamics is well positioned to deliver durable revenue growth and profitability over the long term. Positioned for Sustainable, Long -Term Value Creation